Xenograft News and Research

RSS
Xenograft are the cells of one species transplanted to another species.
LEAD Therapeutics discovers orally available PARP inhibitor

LEAD Therapeutics discovers orally available PARP inhibitor

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

RTI Biologics revenues increases to $42.8 million in third quarter 2009

RTI Biologics revenues increases to $42.8 million in third quarter 2009

AACR to host its first Frontiers in Basic Cancer Research Meeting

AACR to host its first Frontiers in Basic Cancer Research Meeting

Governor’s Business Expansion Award for RTI Biologics

Governor’s Business Expansion Award for RTI Biologics

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

A novel glioblastoma mouse model developed

A novel glioblastoma mouse model developed

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Exelixis files investigational new drug application for anticancer compound

Exelixis files investigational new drug application for anticancer compound

Transapical aortic valve implantation

Transapical aortic valve implantation

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

Cancer prevention

Cancer prevention